Lack of α2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction
Authors:
Open Access
- 1 October 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (7) , 2487-2493
Abstract
Identification of a novel therapy for prevention of sudden death by ischemic cardiac infarction is an area of intensive investigation. We here report that the mortality due to an experimental acute myocardial infarction (AMI) was markedly increased in mice deficient in α2-antiplasmin (α2-AP−/− mice) but not in mice deficient in other components acting in fibrinolysis (tissue-type PA, urokinase type PA, or plasminogen activator inhibitor-1) even if the infarct area in α2-AP−/− mice was not different from those in the other mice. Echocardiography showed in α2-AP−/− mice after AMI an overload of the right ventricle and that pulmonary permeability was increased. According to the experiments using explanted myocytes and vascular smooth muscle cells, it was found that the amount of secreted vascular endothelial cell growth factor (VEGF) in α2-AP−/− mice was markedly increased compared with that in wild-type mice. Finally, an injection of an anti-VEGF antibody decreased the mortality after AMI in α2-AP−/− mice. Plasmin cleaves extracellular matrix-bound VEGF to release a diffusible proteolytic fragment and is inactivated mainly by α2-AP. Therefore, lack of α2-AP could markedly result in overrelease of VEGF by the continuous activation of plasmin because of AMI and could result in an acute cor pulmonale. Our results provide new aspects on the role of α2-AP and VEGF in the pathogenesis of cardiac events.Keywords
This publication has 33 references indexed in Scilit:
- Plasmin-α2-antiplasmin Complex in Patients with Atrial FibrillationThrombosis and Haemostasis, 1999
- Gene Manipulation and Transfer of the Plasminogen and Coagulation System in MiceSeminars in Thrombosis and Hemostasis, 1996
- Development and clinical application of a new ELISA assay to determine plasmin–α2‐antiplasmin complexes in plasmaBritish Journal of Haematology, 1996
- Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Characterization of the Interaction Between Plasminogen and StaphylokinaseEuropean Journal of Biochemistry, 1994
- Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombusBlood, 1993
- Markers of a hypercoagulable state following acute ischemic stroke.Stroke, 1992
- Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.Circulation, 1992
- Molecular mechanism of physiological fibrinolysisNature, 1978
- Identification and Some Properties of a New Fast‐Reacting Plasmin Inhibitor in Human PlasmaEuropean Journal of Biochemistry, 1976